Ren, Z., Liang, T., Gu, S., Gou, H., Peng, C., Pan, Y., . . . Li, D. (2026). First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. Advances in Therapy, 43(9), 3871-3886.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Ren, Zhenggang, et al. "First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study."
Advances in Therapy 43, no. 9 (2026): 3871-3886.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Ren, Zhenggang, et al. "First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study."
Advances in Therapy, vol. 43, no. 9, 2026, pp. 3871-3886.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.